Suggested remit: To appraise the clinical and cost effectiveness of ciltacabtagene autoleucel within its marketing authorisation for relapsed or refractory multiple myeloma.
Status In progress
Process STA 2018
ID number 3816

Provisional Schedule

Committee meeting: 1 09 November 2021
Expected publication 02 February 2022

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors Janssen (ciltacabtagene autoleucel)
Others Department of Health and Social Care
  NHS England
  NHS Lambeth CCG
  NHS Waltham Forest CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia Care
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Myeloma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Haematology
  British Society for Interventional Radiology
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Myeloma Forum
  UK Oncology Nursing Society


Associated guideline groups National Guideline Alliance
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Advanz pharma (dexamethasone)
  Amgen (carfilzomib)
  Aspen (dexamethasone)
  Aspire pharma (bortezomib, dexamethasone)
  Celgene (lenalidomide, pomalidomide)
  Consilient health (dexamethasone)
  Dr Reddy’s laboratories (bortezomib)
  Glenmark pharmaceuricals (dexamethasone)
  Janssen-Cilag (bortezomib)
  Martindale pharma (dexamethasone)
  Mylan (bortezomib)
  Novartis pharmaceuticals (panobinostat)
  Teva (dexamethasone)
  Thornton & Ross (bortezomib)
  Rosemont pharmaceuticals limited (dexamethasone)
  Zentiva (bortezomib)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Genomics England
  Institute of Cancer Research
  Leukaemia UK
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
12 March 2021 Invitation to participate
14 January 2021 - 11 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 March 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance